| 000 | 01823 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514011022.0 | ||
| 264 | 0 | _c20011004 | |
| 008 | 200110s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/hc3601.095576 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHilgers, K F | |
| 245 | 0 | 0 |
_aAngiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. _h[electronic resource] |
| 260 |
_bCirculation _cSep 2001 |
||
| 300 |
_a1436-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAngiotensin Receptor Antagonists |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xpharmacology |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 |
_aChemokine CCL2 _xbiosynthesis |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aHypertension, Malignant _xetiology |
| 650 | 0 | 4 |
_aHypertension, Renovascular _xcomplications |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aMacrophages _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNephritis _xcomplications |
| 650 | 0 | 4 |
_aOrgan Size _xdrug effects |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aReceptor, Angiotensin, Type 1 |
| 650 | 0 | 4 | _aReceptor, Angiotensin, Type 2 |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 | _aValsartan |
| 700 | 1 | _aHartner, A | |
| 700 | 1 | _aPorst, M | |
| 700 | 1 | _aVeelken, R | |
| 700 | 1 | _aMann, J F | |
| 773 | 0 |
_tCirculation _gvol. 104 _gno. 12 _gp. 1436-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/hc3601.095576 _zAvailable from publisher's website |
| 999 |
_c11482968 _d11482968 |
||